Business Wire

I-CARE

15.2.2024 14:31:33 CET | Business Wire | Press release

Share
I-care Launches the Wi-care 130 G23, a 100% Belgian High-precision Vibration Sensor With 3 Times More Powerful Data Flow

I-care, world leader in machine health, today presented the latest innovation in its Wi-care product range, the Wi-care 130 G23. This is the very first high-precision vibration sensor manufactured entirely in Belgium, capable of predicting more and more industrial breakdowns at an ever earlier stage. It is 100% autonomous, and therefore wireless, with a data flow that is 3 times more powerful and a battery life of 5 years. Thanks to this new technological innovation, I-care is strengthening AI-powered industrial maintenance 4.0. and enabling industries around the world to be more productive, safer and more sustainable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215735570/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wi-care 130 G23 (Photo: I-care)

The Wi-care 130 G23, the very first sensor to be manufactured entirely in Belgium, is a revolution in the predictive maintenance business. It is an innovative tool capable of carrying out 3 types of measurement on machines simultaneously: vibration analysis, shock identification and temperature monitoring. It incorporates the state-of-the-art technologies, in particular piezoelectric sensors, and works on all types of industrial machine.

The Wi-care 130 G23 is 100% autonomous, and therefore wireless. It has a battery that will last for more than 5 years of uninterrupted use, even when taking high-precision measurements that consume a lot of energy. The sensor is ATEX certified, with a data stream 3 times more powerful, offering high resolution and high frequency.

Like all products in the Wi-care range, this new sensor from I-care is fully integrated into the WaaS (Wi-care as a Service) ecosystem, an all-inclusive machine maintenance solution covering everything from hardware to support services via the iSee platform, including analysis and reporting. .

I-care is an expert in analysing machine vibrations to predict industrial failures months or even years before they occur. The Wi-care 130 G23 enables errors to be detected at an early stage, so that more and more industrial failures can be predicted earlier and earlier. In this way, I-care is delivering on its mission to "change the way the world works" by making industries around the world more efficient, safer and more environmentally friendly.

"With the Wi-care 130 G23, not only the design but also, and above all, the performance of Wi-care has been enormously improved. It's a real revolution, and 100% Belgian," says Fabrice Brion, CEO of I-care. "Above all, it's about enabling the industrial manufacturing companies to work better. At I-care, this is our way of contributing to a more efficient and sustainable economy.”

About I-care
The I-care Group is a world leader in machine health. Our mission is to change the way the world works. Our AI and data-driven solutions predict industrial failures months or even years before they occur. Thanks to I-care, machines around the world are safer, more productive and more sustainable. Founded in 2004 in Mons, Belgium, we employ over 800 people, with 36 offices in 16 countries (Asia-Pacific, EMEA and the US) and customers in over 55 countries.

Pictures Wi-care 130 G23

Please find the pictures of the Wi-care 130 G23 here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215735570/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye